Trials / Completed
CompletedNCT05448339
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 197 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | PVHA or TACE | PVHA or TACE |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2023-12-31
- Completion
- 2024-01-01
- First posted
- 2022-07-07
- Last updated
- 2024-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05448339. Inclusion in this directory is not an endorsement.